The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
Open accessAbstract
SUMMARY Herein we report that the VEGFR/PDGFR kinase inhibitor sunitinib/SU11248 can accelerate metastatic tumor growth and decrease overall survival in mice receiving short-term therapy in various metastasis assays, including after intravenous injection of tumor cells or after removal of primary orthotopically grown tumors. Acceleration of metastasis was also observed in mice receiving sunitinib prior to intravenous implantation of tumor cells, suggesting possible “metastatic conditioning” in multiple organs. Similar findings with additional VEGF receptor tyrosine kinase inhibitors implicate a class-specific effect for such agents. Importantly, these observations of metastatic acceleration were in contrast to the demonstrable antitumor benefits obtained when the same human breast cancer cells, as well as mouse or human melanoma cells, were grown orthotopically as primary tumors and subjected to identical sunitinib treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., MacDonald, D. D., Jin, D. K., Shido, K., Kerns, S. A., et al. (2005) · Nature · doi:10.1038/nature04186 · Cited by 3,288
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
Angiogenesis: an organizing principle for drug discovery?
Folkman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2115 · Cited by 2,246
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
VEGF-Induced Adult Neovascularization: Recruitment, Retention, and Role of Accessory Cells
Grunewald, M., Avraham, I., Dor, Y., Bachar-Lustig, E., Itin, A., Yung, S., Chimenti, S., Landsman, L., Abramovitch, R., & Keshet, E. (2006) · Cell · doi:10.1016/j.cell.2005.10.036 · Cited by 1,126
Rapid vascular regrowth in tumors after reversal of VEGF inhibition
Mancuso, M. R., Davis, R., Norberg, S. M., O'Brien, S., Sennino, B., Nakahara, T., Yao, V. J., Inai, T., Brooks, P., Freimark, B., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24612 · Cited by 809
Burstein, H. J., Elias, A. D., Rugo, H. S., Cobleigh, M. A., Wolff, A. C., Eisenberg, P. D., Lehman, M., Adams, B. J., Bello, C. L., DePrimo, S. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5375 · Cited by 489
Systemic Endocrine Instigation of Indolent Tumor Growth Requires Osteopontin
McAllister, S. S., Gifford, A. M., Greiner, A. L., Kelleher, S. P., Saelzler, M. P., Ince, T. A., Reinhardt, F., Harris, L. N., Hylander, B. L., Repasky, E. A., et al. (2008) · Cell · doi:10.1016/j.cell.2008.04.045 · Cited by 431
Cited by
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
Tumor Metastasis: Molecular Insights and Evolving Paradigms
Valastyan, S., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.09.024 · Cited by 4,011
Integrins in cancer: biological implications and therapeutic opportunities
Desgrosellier, J. S., & Cheresh, D. A. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2748 · Cited by 3,736
Hypoxia-inducible factors in physiology and medicine
Semenza, G. L. (2012) · Cell · doi:10.1016/j.cell.2012.01.021 · Cited by 3,645
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Influence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
Intra-tumour heterogeneity: a looking glass for cancer?
Marusyk, A., Almendro, V., & Polyak, K. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3261 · Cited by 2,000
Tumor angiogenesis: causes, consequences, challenges and opportunities
Lugano, R., Ramachandran, M., & Dimberg, A. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03351-7 · Cited by 1,986
Tumor angiogenesis: molecular pathways and therapeutic targets
Weis, S. M., & Cheresh, D. A. (2011) · Nature Medicine · doi:10.1038/nm.2537 · Cited by 1,736
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
Carmeliet, P., & Jain, R. K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3455 · Cited by 1,675
Signal transduction by vascular endothelial growth factor receptors
Koch, S., Tugues, S., Li, X., Gualandi, L., & Claesson-Welsh, L. (2011) · Biochemical Journal · doi:10.1042/bj20110301 · Cited by 1,635
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
Semenza, G. L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.01.005 · Cited by 1,514
Goldhirsch, A., Ingle, J. N., Gelber, R. D., Coates, A. S., Thürlimann, B., & Senn, H.-J. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp322 · Cited by 1,374
Steeg, P. S. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.25 · Cited by 1,363
Yakes, F. M., Chen, J., Tan, J., Yamaguchi, K., Shi, Y., Yu, P., Qian, F., Chu, F., Bentzien, F., Cancilla, B., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0264 · Cited by 1,336
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
Hypoxia-Induced Angiogenesis: Good and Evil
Krock, B. L., Skuli, N., & Simon, M. C. (2011) · Genes & Cancer · doi:10.1177/1947601911423654 · Cited by 1,180
Defining normoxia, physoxia and hypoxia in tumours—implications for treatment response
McKeown, S. R. (2014) · The British Journal of Radiology · doi:10.1259/bjr.20130676 · Cited by 1,050
Ten years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,030
Pancreatic cancer stroma: an update on therapeutic targeting strategies
Hosein, A. N., Brekken, R. A., & Maitra, A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0300-1 · Cited by 950
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
Tian, L., Goldstein, A., Wang, H., Ching Lo, H., Sun Kim, I., Welte, T., Sheng, K., Dobrolecki, L. E., Zhang, X., Putluri, N., et al. (2017) · Nature · doi:10.1038/nature21724 · Cited by 841
Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
Allen, E., Jabouille, A., Rivera, L. B., Lodewijckx, I., Missiaen, R., Steri, V., Feyen, K., Tawney, J., Hanahan, D., Michael, I. P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9679 · Cited by 820
Heddleston, J. M., Li, Z., McLendon, R. E., Hjelmeland, A. B., & Rich, J. N. (2009) · Cell Cycle · doi:10.4161/cc.8.20.9701 · Cited by 813
Johnson, P. J., Qin, S., Park, J.-W., Poon, R. T. P., Raoul, J.-L., Philip, P. A., Hsu, C.-H., Hu, T.-H., Heo, J., Xu, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4410 · Cited by 772
Lou, Y., McDonald, P. C., Oloumi, A., Chia, S., Ostlund, C., Ahmadi, A., Kyle, A., auf dem Keller, U., Leung, S., Huntsman, D., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4261 · Cited by 755
Targeting the tumour vasculature: insights from physiological angiogenesis
Chung, A. S., Lee, J., & Ferrara, N. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2868 · Cited by 752
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Vasudev, N. S., & Reynolds, A. R. (2014) · Angiogenesis · doi:10.1007/s10456-014-9420-y · Cited by 738
Hypoxia and hypoxia-inducible factors: master regulators of metastasis
Lu, X., & Kang, Y. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1360 · Cited by 723
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
Ebos, J. M. L., & Kerbel, R. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.21 · Cited by 685
“The first finding comes from two preclinical studies showing that the benefits from VEGF-pathway-inhibitor monotherapy can depend on disease stage and treatment circumstances and can, in certain settings, be offset by increased aggressive invasiveness and augmented metastatic potential”
BackgroundSelf-citationAntiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia
Conley, S. J., Gheordunescu, E., Kakarala, P., Newman, B., Korkaya, H., Heath, A. N., Clouthier, S. G., & Wicha, M. S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018866109 · Cited by 663
Metronomic chemotherapy: new rationale for new directions
Pasquier, E., Kavallaris, M., & André, N. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.82 · Cited by 659
Mazzieri, R., Pucci, F., Moi, D., Zonari, E., Ranghetti, A., Berti, A., Politi, L. S., Gentner, B., Brown, J. L., Naldini, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.02.005 · Cited by 639
The therapeutic promise of the cancer stem cell concept
Frank, N. Y., Schatton, T., & Frank, M. H. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41004 · Cited by 636
Haas, N. B., Manola, J., Uzzo, R. G., Flaherty, K. T., Wood, C. G., Kane, C., Jewett, M., Dutcher, J. P., Atkins, M. B., Pins, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00559-6 · Cited by 630
The angiogenic switch in carcinogenesis
Baeriswyl, V., & Christofori, G. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.05.003 · Cited by 625
Breast cancer stem cells, cytokine networks, and the tumor microenvironment
Korkaya, H., Liu, S., & Wicha, M. S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57099 · Cited by 616
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Yi, M., Jiao, D., Qin, S., Chu, Q., Wu, K., & Li, A. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0974-6 · Cited by 608
Nitric Oxide: Physiological Functions, Delivery, and Biomedical Applications
Andrabi, S. M., Sharma, N. S., Karan, A., Shahriar, S. M. S., Cordon, B., Ma, B., & Xie, J. (2023) · Advanced Science · doi:10.1002/advs.202303259 · Cited by 602
Allegra, C. J., Yothers, G., O'Connell, M. J., Sharif, S., Petrelli, N. J., Colangelo, L. H., Atkins, J. N., Seay, T. E., Fehrenbacher, L., Goldberg, R. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.0855 · Cited by 593
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer
Welti, J., Loges, S., Dimmeler, S., & Carmeliet, P. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70212 · Cited by 591
Classical Mathematical Models for Description and Prediction of Experimental Tumor Growth
Benzekry, S., Lamont, C., Beheshti, A., Tracz, A., Ebos, J. M. L., Hlatky, L., & Hahnfeldt, P. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003800 · Cited by 587
Self-citationHypoxia-inducible factors: cancer progression and clinical translation
Wicks, E. E., & Semenza, G. L. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159839 · Cited by 580
Butler, J. M., Kobayashi, H., & Rafii, S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2791 · Cited by 578
Biomarkers of response and resistance to antiangiogenic therapy
Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeffler, J. S., Batchelor, T. T., & Sorensen, A. G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.63 · Cited by 572
Homeostatic chemokine receptors and organ-specific metastasis
Zlotnik, A., Burkhardt, A. M., & Homey, B. (2011) · Nature Reviews Immunology · doi:10.1038/nri3049 · Cited by 571
HCC and angiogenesis: possible targets and future directions
Zhu, A. X., Duda, D. G., Sahani, D. V., & Jain, R. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.30 · Cited by 564
Luo, B., & Lee, A. S. (2013) · Oncogene · doi:10.1038/onc.2012.130 · Cited by 560
Holland, S. J., Pan, A., Franci, C., Hu, Y., Chang, B., Li, W., Duan, M., Torneros, A., Yu, J., Heckrodt, T. J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2997 · Cited by 550
Improving drug delivery to solid tumors: Priming the tumor microenvironment
Khawar, I. A., Kim, J. H., & Kuh, H.-J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.018 · Cited by 533
Cooke, V. G., LeBleu, V. S., Keskin, D., Khan, Z., O'Connell, J. T., Teng, Y., Duncan, M. B., Xie, L., Maeda, G., Vong, S., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.024 · Cited by 530
Malignant Glioma: Lessons from Genomics, Mouse Models, and Stem Cells
Chen, J., McKay, R. M., & Parada, L. F. (2012) · Cell · doi:10.1016/j.cell.2012.03.009 · Cited by 527
The Contribution of Angiogenesis to the Process of Metastasis
Bielenberg, D. R., & Zetter, B. R. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000138 · Cited by 523
Batchelor, T. T., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Plotkin, S. R., Gerstner, E., Eichler, A. F., Drappatz, J., Hochberg, F. H., Benner, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3988 · Cited by 520
Pacchiano, F., Carta, F., McDonald, P. C., Lou, Y., Vullo, D., Scozzafava, A., Dedhar, S., & Supuran, C. T. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101541x · Cited by 519
Role of the Tumor Microenvironment in Breast Cancer
Soysal, S. D., Tzankov, A., & Muenst, S. E. (2015) · Pathobiology · doi:10.1159/000430499 · Cited by 510
VEGF and angiopoietin signaling in tumor angiogenesis and metastasis
Saharinen, P., Eklund, L., Pulkki, K., Bono, P., & Alitalo, K. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.01.015 · Cited by 478
Use of the mouse aortic ring assay to study angiogenesis
Baker, M., Robinson, S. D., Lechertier, T., Barber, P. R., Tavora, B., D'Amico, G., Jones, D. T., Vojnovic, B., & Hodivala-Dilke, K. (2012) · Nature Protocols · doi:10.1038/nprot.2011.435 · Cited by 477
Mechanisms of Glioma-Associated Neovascularization
Hardee, M. E., & Zagzag, D. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.06.030 · Cited by 475
Targeting the ANGPT–TIE2 pathway in malignancy
Huang, H., Bhat, A., Woodnutt, G., & Lappe, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2894 · Cited by 468
Broad targeting of angiogenesis for cancer prevention and therapy
Wang, Z., Dabrosin, C., Yin, X., Fuster, M. M., Arreola, A., Rathmell, W. K., Generali, D., Nagaraju, G. P., El-Rayes, B., Ribatti, D., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.01.001 · Cited by 464
Kuczynski, E. A., Vermeulen, P. B., Pezzella, F., Kerbel, R. S., & Reynolds, A. R. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0181-9 · Cited by 446
Self-citationLiang, C., Xu, L., Song, G., & Liu, Z. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00458j · Cited by 435
Geiger, T. R., & Peeper, D. S. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.07.006 · Cited by 431
Deryugina, E. I., & Quigley, J. P. (2015) · Matrix Biology · doi:10.1016/j.matbio.2015.04.004 · Cited by 422
Dudley, A. C. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006536 · Cited by 424
The microenvironment in breast cancer progression: biology and implications for treatment
Place, A. E., Jin Huh, S., & Polyak, K. (2011) · Breast Cancer Research · doi:10.1186/bcr2912 · Cited by 413
Sennino, B., Ishiguro-Oonuma, T., Wei, Y., Naylor, R. M., Williamson, C. W., Bhagwandin, V., Tabruyn, S. P., You, W.-K., Chapman, H. A., Christensen, J. G., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0240 · Cited by 408
Self-citationUnravelling the complexity of metastasis — molecular understanding and targeted therapies
Sethi, N., & Kang, Y. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3125 · Cited by 397
Fornari, F., Milazzo, M., Chieco, P., Negrini, M., Calin, G. A., Grazi, G. L., Pollutri, D., Croce, C. M., Bolondi, L., & Gramantieri, L. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0145 · Cited by 396
Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
Haibe, Y., Kreidieh, M., El Hajj, H., Khalifeh, I., Mukherji, D., Temraz, S., & Shamseddine, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00221 · Cited by 396
Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited
Loges, S., Mazzone, M., Hohensinner, P., & Carmeliet, P. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.007 · Cited by 393
Fibronectin, the extracellular glue
Zollinger, A. J., & Smith, M. L. (2017) · Matrix Biology · doi:10.1016/j.matbio.2016.07.011 · Cited by 383
Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy
Comoglio, P. M., Trusolino, L., & Boccaccio, C. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0002-y · Cited by 381
Pseudoprogression and pseudoresponse in the treatment of gliomas
Brandsma, D., & van den Bent, M. J. (2009) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328332363e · Cited by 378
ATF4 Regulates MYC-Mediated Neuroblastoma Cell Death upon Glutamine Deprivation
Qing, G., Li, B., Vu, A., Skuli, N., Walton, Z. E., Liu, X., Mayes, P. A., Wise, D. R., Thompson, C. B., Maris, J. M., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.021 · Cited by 375
Zhang, W., Zhu, X.-D., Sun, H.-C., Xiong, Y.-Q., Zhuang, P.-Y., Xu, H.-X., Kong, L.-Q., Wang, L., Wu, W.-Z., & Tang, Z.-Y. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2904 · Cited by 374
Ovarian cancer cell-secreted exosomal miR-205 promotes metastasis by inducing angiogenesis
He, L., Zhu, W., Chen, Q., Yuan, Y., Wang, Y., Wang, J., & Wu, X. (2019) · Theranostics · doi:10.7150/thno.37455 · Cited by 367
Priceman, S. J., Sung, J. L., Shaposhnik, Z., Burton, J. B., Torres-Collado, A. X., Moughon, D. L., Johnson, M., Lusis, A. J., Cohen, D. A., Iruela-Arispe, M. L., et al. (2010) · Blood · doi:10.1182/blood-2009-08-237412 · Cited by 356
Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.
Goel, S., Wong, A. H.-K., & Jain, R. K. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006486 · Cited by 352
Mitochondrial oxidative stress in the tumor microenvironment and cancer immunoescape: foe or friend?
Kuo, C.-L., Ponneri Babuharisankar, A., Lin, Y.-C., Lien, H.-W., Lo, Y. K., Chou, H.-Y., Tangeda, V., Cheng, L.-C., Cheng, A. N., & Lee, A. Y.-L. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00859-2 · Cited by 351
Koh, M. Y., Lemos, R., Liu, X., & Powis, G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4142 · Cited by 350
“Intriguingly, chronic hypoxia has been implicated as a causal factor for the increased aggressiveness of tumors that develop resistance to antiangiogenic therapy such as to VEGF inhibition (40, 41), underscoring the need for a clearer understanding of the mechanisms that regulate the responses of the chronic versus ac…”
Strategies for the discovery and development of therapies for metastatic breast cancer
Eckhardt, B. L., Francis, P. A., Parker, B. S., & Anderson, R. L. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd2372 · Cited by 349
Anti-angiogenesis therapy in cancer: Current challenges and future perspectives
Shojaei, F. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.03.008 · Cited by 348
Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche
Lock, F. E., McDonald, P. C., Lou, Y., Serrano, I., Chafe, S. C., Ostlund, C., Aparicio, S., Winum, J.-Y., Supuran, C. T., & Dedhar, S. (2013) · Oncogene · doi:10.1038/onc.2012.550 · Cited by 348
Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway
Itatani, Y., Kawada, K., Yamamoto, T., & Sakai, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041232 · Cited by 346
Modi, S. J., & Kulkarni, V. M. (2019) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2019.100009 · Cited by 320
HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors
Shojaei, F., Lee, J. H., Simmons, B. H., Wong, A., Esparza, C. O., Plumlee, P. A., Feng, J., Stewart, A. E., Hu-Lowe, D. D., & Christensen, J. G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0489 · Cited by 319
Self-citationVHL and HIF signalling in renal cell carcinogenesis
Baldewijns, M. M., van Vlodrop, I. J., Vermeulen, P. B., Soetekouw, P. M., van Engeland, M., & de Bruïne, A. P. (2010) · The Journal of Pathology · doi:10.1002/path.2689 · Cited by 316
Tartour, E., Pere, H., Maillere, B., Terme, M., Merillon, N., Taieb, J., Sandoval, F., Quintin-Colonna, F., Lacerda, K., Karadimou, A., et al. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9281-4 · Cited by 316
Targeting angiogenesis in oncology, ophthalmology and beyond
Cao, Y., Langer, R., & Ferrara, N. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00671-z · Cited by 315
Pathways mediating VEGF-independent tumor angiogenesis
Ferrara, N. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.003 · Cited by 313
Metal-based drugs that break the rules
Allardyce, C. S., & Dyson, P. J. (2016) · Dalton Transactions · doi:10.1039/c5dt03919c · Cited by 308
Mouse models of metastasis: progress and prospects
Gómez-Cuadrado, L., Tracey, N., Ma, R., Qian, B., & Brunton, V. G. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.030403 · Cited by 301
Ko, J. S., Rayman, P., Ireland, J., Swaidani, S., Li, G., Bunting, K. D., Rini, B., Finke, J. H., & Cohen, P. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3278 · Cited by 296
Ebos, J. M. L., Lee, C. R., & Kerbel, R. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0095 · Cited by 291
Self-citationAntiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?
De Bock, K., Mazzone, M., & Carmeliet, P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.83 · Cited by 293
The immune system in cancer metastasis: friend or foe?
Janssen, L. M. E., Ramsay, E. E., Logsdon, C. D., & Overwijk, W. W. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0283-9 · Cited by 292
Liang, Y., Zheng, T., Song, R., Wang, J., Yin, D., Wang, L., Liu, H., Tian, L., Fang, X., Meng, X., et al. (2013) · Hepatology · doi:10.1002/hep.26224 · Cited by 289
Metadata
- Authors
- Ebos, J. M. L., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2009-03
- Volume
- 15
- Issue
- 3
- Pages
- 232-239
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W1967600348
- Cited by
- 1,709
- References
- 29
- FWCI
- 78.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.